{"id":"ir103","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for IR103 are limited in public literature, the drug appears to be developed by Immune Response BioPharma as an immunomodulatory therapeutic. Given the company's focus and the drug's phase 3 status, it likely works through enhancement of T-cell mediated immunity or checkpoint modulation to treat cancer or infectious diseases.","oneSentence":"IR103 is an immunotherapeutic agent designed to modulate immune response, likely through activation or enhancement of anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:51.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02366026","phase":"PHASE3","title":"REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study","status":"UNKNOWN","sponsor":"Immune Response BioPharma, Inc.","startDate":"2017-06","conditions":"HIV","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HIV-1 IMMUNOGEN + Amplivax","REMUNE + Amplivax"],"phase":"phase_3","status":"active","brandName":"IR103","genericName":"IR103","companyName":"Immune Response BioPharma, Inc.","companyId":"immune-response-biopharma-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}